Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study

G. Mangili, J. Ottolina, G. Cormio, Vera Loizzi, P. De Iaco, D. A. Pellegrini, M. Candiani, G. Giorda, G. Scarfone, S. C. Cecere, L. Frigerio, A. Gadducci, C. Marchetti, G. Ferrandina

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective Evidence-based management of granulosa cell tumors of the ovary (GCT) has been not yet standardized: surgery, including fertility-sparing procedures for young women, has been traditionally the standard treatment; on the other hand, chemotherapy has been used for treatment of advanced and/or recurrent disease. However, very limited experience, has been selectively focused on the role of adjuvant chemotherapy in stage IC patients. The objective of this retrospective study was to assess the efficacy of first line postoperative chemotherapy in patients with stage IC treated at the Italian Centers involved in the MITO (Multicenter Italian Trials in Ovarian cancer) Group. Patients and methods A retrospective multi-institutional review of patients with GCT of the ovary at FIGO stage IC treated or referred to MITO centers was conducted. Surgical outcome, pathological findings and follow-up data were analysed. Kaplan–Meier and Cox proportional hazards analyses were used to determine the predictors factors for disease free survival. Results A total of 40 patients with primary GCT of the ovary at FIGO stage IC were identified. The median follow-up period was 96 months (range 7–300). At multivariate analysis, surgical treatment outside MITO centers and incomplete surgical staging were independent poor prognostic indicators for recurrence; adjuvant chemotherapy did not retain significant predictive value for recurrence. Conclusions This study raises the question about the value of adjuvant chemotherapy in stage IC GCT: a comprehensive evaluation of a larger series is urgently needed in order to characterize stage IC substages who can be spared treatment toxicity.

Original languageEnglish
Pages (from-to)276-280
Number of pages5
JournalGynecologic Oncology
Volume143
Issue number2
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Granulosa Cell Tumor
Adjuvant Chemotherapy
Ovarian Neoplasms
Multicenter Studies
Disease-Free Survival
Ovary
Recurrence
Drug Therapy
Therapeutics
Fertility
Multivariate Analysis
Retrospective Studies
Granulosa cell tumor of the ovary

Keywords

  • Adjuvant chemotherapy
  • Granulosa cell tumors of the ovary
  • MITO
  • Prognostic factors
  • Relapse
  • Stage IC

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors : The MITO-9 study. / Mangili, G.; Ottolina, J.; Cormio, G.; Loizzi, Vera; De Iaco, P.; Pellegrini, D. A.; Candiani, M.; Giorda, G.; Scarfone, G.; Cecere, S. C.; Frigerio, L.; Gadducci, A.; Marchetti, C.; Ferrandina, G.

In: Gynecologic Oncology, Vol. 143, No. 2, 01.11.2016, p. 276-280.

Research output: Contribution to journalArticle

Mangili, G. ; Ottolina, J. ; Cormio, G. ; Loizzi, Vera ; De Iaco, P. ; Pellegrini, D. A. ; Candiani, M. ; Giorda, G. ; Scarfone, G. ; Cecere, S. C. ; Frigerio, L. ; Gadducci, A. ; Marchetti, C. ; Ferrandina, G. / Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors : The MITO-9 study. In: Gynecologic Oncology. 2016 ; Vol. 143, No. 2. pp. 276-280.
@article{ff3f191be8334b858d4e22f10c3f6570,
title = "Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study",
abstract = "Objective Evidence-based management of granulosa cell tumors of the ovary (GCT) has been not yet standardized: surgery, including fertility-sparing procedures for young women, has been traditionally the standard treatment; on the other hand, chemotherapy has been used for treatment of advanced and/or recurrent disease. However, very limited experience, has been selectively focused on the role of adjuvant chemotherapy in stage IC patients. The objective of this retrospective study was to assess the efficacy of first line postoperative chemotherapy in patients with stage IC treated at the Italian Centers involved in the MITO (Multicenter Italian Trials in Ovarian cancer) Group. Patients and methods A retrospective multi-institutional review of patients with GCT of the ovary at FIGO stage IC treated or referred to MITO centers was conducted. Surgical outcome, pathological findings and follow-up data were analysed. Kaplan–Meier and Cox proportional hazards analyses were used to determine the predictors factors for disease free survival. Results A total of 40 patients with primary GCT of the ovary at FIGO stage IC were identified. The median follow-up period was 96 months (range 7–300). At multivariate analysis, surgical treatment outside MITO centers and incomplete surgical staging were independent poor prognostic indicators for recurrence; adjuvant chemotherapy did not retain significant predictive value for recurrence. Conclusions This study raises the question about the value of adjuvant chemotherapy in stage IC GCT: a comprehensive evaluation of a larger series is urgently needed in order to characterize stage IC substages who can be spared treatment toxicity.",
keywords = "Adjuvant chemotherapy, Granulosa cell tumors of the ovary, MITO, Prognostic factors, Relapse, Stage IC",
author = "G. Mangili and J. Ottolina and G. Cormio and Vera Loizzi and {De Iaco}, P. and Pellegrini, {D. A.} and M. Candiani and G. Giorda and G. Scarfone and Cecere, {S. C.} and L. Frigerio and A. Gadducci and C. Marchetti and G. Ferrandina",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.ygyno.2016.08.316",
language = "English",
volume = "143",
pages = "276--280",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors

T2 - The MITO-9 study

AU - Mangili, G.

AU - Ottolina, J.

AU - Cormio, G.

AU - Loizzi, Vera

AU - De Iaco, P.

AU - Pellegrini, D. A.

AU - Candiani, M.

AU - Giorda, G.

AU - Scarfone, G.

AU - Cecere, S. C.

AU - Frigerio, L.

AU - Gadducci, A.

AU - Marchetti, C.

AU - Ferrandina, G.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective Evidence-based management of granulosa cell tumors of the ovary (GCT) has been not yet standardized: surgery, including fertility-sparing procedures for young women, has been traditionally the standard treatment; on the other hand, chemotherapy has been used for treatment of advanced and/or recurrent disease. However, very limited experience, has been selectively focused on the role of adjuvant chemotherapy in stage IC patients. The objective of this retrospective study was to assess the efficacy of first line postoperative chemotherapy in patients with stage IC treated at the Italian Centers involved in the MITO (Multicenter Italian Trials in Ovarian cancer) Group. Patients and methods A retrospective multi-institutional review of patients with GCT of the ovary at FIGO stage IC treated or referred to MITO centers was conducted. Surgical outcome, pathological findings and follow-up data were analysed. Kaplan–Meier and Cox proportional hazards analyses were used to determine the predictors factors for disease free survival. Results A total of 40 patients with primary GCT of the ovary at FIGO stage IC were identified. The median follow-up period was 96 months (range 7–300). At multivariate analysis, surgical treatment outside MITO centers and incomplete surgical staging were independent poor prognostic indicators for recurrence; adjuvant chemotherapy did not retain significant predictive value for recurrence. Conclusions This study raises the question about the value of adjuvant chemotherapy in stage IC GCT: a comprehensive evaluation of a larger series is urgently needed in order to characterize stage IC substages who can be spared treatment toxicity.

AB - Objective Evidence-based management of granulosa cell tumors of the ovary (GCT) has been not yet standardized: surgery, including fertility-sparing procedures for young women, has been traditionally the standard treatment; on the other hand, chemotherapy has been used for treatment of advanced and/or recurrent disease. However, very limited experience, has been selectively focused on the role of adjuvant chemotherapy in stage IC patients. The objective of this retrospective study was to assess the efficacy of first line postoperative chemotherapy in patients with stage IC treated at the Italian Centers involved in the MITO (Multicenter Italian Trials in Ovarian cancer) Group. Patients and methods A retrospective multi-institutional review of patients with GCT of the ovary at FIGO stage IC treated or referred to MITO centers was conducted. Surgical outcome, pathological findings and follow-up data were analysed. Kaplan–Meier and Cox proportional hazards analyses were used to determine the predictors factors for disease free survival. Results A total of 40 patients with primary GCT of the ovary at FIGO stage IC were identified. The median follow-up period was 96 months (range 7–300). At multivariate analysis, surgical treatment outside MITO centers and incomplete surgical staging were independent poor prognostic indicators for recurrence; adjuvant chemotherapy did not retain significant predictive value for recurrence. Conclusions This study raises the question about the value of adjuvant chemotherapy in stage IC GCT: a comprehensive evaluation of a larger series is urgently needed in order to characterize stage IC substages who can be spared treatment toxicity.

KW - Adjuvant chemotherapy

KW - Granulosa cell tumors of the ovary

KW - MITO

KW - Prognostic factors

KW - Relapse

KW - Stage IC

UR - http://www.scopus.com/inward/record.url?scp=84994807308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994807308&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.08.316

DO - 10.1016/j.ygyno.2016.08.316

M3 - Article

AN - SCOPUS:84994807308

VL - 143

SP - 276

EP - 280

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -